A New Hormonal Therapy for Prostatic Cancer: Long‐term Clinical and Hormonal Response | Zendy

AHMED S. R. | Zendy; GRANT J. B. F. | Zendy; SHALET S. M. | Zendy; HOWELL A. | Zendy; COSTELLO C. B. | Zendy; WEATHERSON T. | Zendy; BLACKLOCK N. J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

A New Hormonal Therapy for Prostatic Cancer: Long‐term Clinical and Hormonal Response

Author(s) -

AHMED S. R.,

GRANT J. B. F.,

SHALET S. M.,

HOWELL A.,

COSTELLO C. B.,

WEATHERSON T.,

BLACKLOCK N. J.

Publication year - 1986

Publication title -

british journal of urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.773

H-Index - 148

eISSN - 1464-410X

pISSN - 0007-1331

DOI - 10.1111/j.1464-410x.1986.tb05462.x

Subject(s) - testosterone (patch) , hormone , medicine , hormonal therapy , endocrinology , cancer , prostate cancer , urology , physiology , oncology

Summary— Twenty‐four patients with advanced prostatic cancer were treated with daily injections of the LHRH analogue ICI 118630 (Zoladex) for up to 21/2 years. Successful long‐term suppression of LH (luteinising hormone) and testosterone was observed without any escape of testosterone. Immunoreactive LH concentrations rose significantly following the daily injection of LHRH analogue but there was no corresponding rise in testosterone concentrations, suggesting altered bioactivity of the LH. A long‐term clinical response was obtained in 10 patients (41.6%) and the median duration of response in these patients was 25 months. Eight of the 10 had well to moderately differentiated tumours. The actuarial median survival of all patients was 22 months.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research